piraleps 100mg film coated tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - topiramate - film coated tablets - 100mg - topiramate (0097240794) 100mg - topiramate
selegos 5mg tablets
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - selegiline hydrochloride - tablets - 5mg - selegiline hydrochloride (0014611520) 5mg - selegiline
selex 5mg tablets
codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - selegiline hydrochloride - tablets - 5mg - selegiline hydrochloride (0014611520) 5mg - selegiline
strepfen orange sugar free 8.75mg lozenge
reckitt benckiser hellas healthcare sa (0000011401) taki kavalieratou 7, kifisia, athens, 145 64 - flurbiprofen - lozenge - 8.75mg - flurbiprofen (0005104494) 8,75mg - flurbiprofen
zomig 2.5mg film coated tablets
c g papaloisou ltd (0000003113) 35 kilkis avenue, lefkosia, 2234 - zolmitriptan - film coated tablets - 2.5mg - zolmitriptan (8000001610) 2,5mg - zolmitriptan
klisyri
almirall, s.a. - tirbanibulin - Κερατόζης, Ακτινικός - Αντιβιοτικά και χημειοθεραπευτικά για δερματολογική χρήση - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
okedi
laboratorios farmacéuticos rovi, s.a. - risperidone - Σχιζοφρένεια - Ψυχοληπτικά - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
ertapenem sun
sun pharmaceutical industries (europe) b.v. - ertapenem sodium - Βακτηριακές λοιμώξεις - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 και 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. Πρέπει να ληφθούν υπόψη οι επίσημες οδηγίες για την κατάλληλη χρήση των αντιβακτηριακών παραγόντων.
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - Ομοιοστασία ασβεστίου - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.